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Neovascularization is essential for growth of and nutrition to solid
tumours greater than 2 mm in diameter (Folkman, 1985). Among
angiogenic factors, VEGF was initially recognized as a vascular
permeability factor (34–42 kDa) that induced tumour ascites
(Senger et al, 1983). Afterward, VEGF was identified as a vascular
permeability factor that is active in increasing blood vessel perme-
ability, endothelial cell growth and angiogenesis (Leung et al,
1989). Similarly, it was described as having a direct-acting
mitogen specific for vascular endothelial cells (Keck et al, 1989).
VEGF is expressed in tissues with rapid vascular endothelial
turnover, which are reproductive organs such as ovary, uterus and
placenta, and in tumours (Garrido et al, 1993; Li et al, 1994;
Jackson et al, 1994). The level of VEGF correlates with
microvessel density, but not with worsened patient prognosis in
uterine cervical cancers (Fujimoto et al, 1999a). The expression of
VEGF was down-regulated with advancement of uterine endome-
trial cancers lacking sex steroidal dependency (Fujimoto et al,
1998a, 1999b). In ovarian cancers, the expression of VEGF has
been well demonstrated (Boocock et al, 1995; Abu-Jawdeh et al,
1996; Paley et al, 1997), and since the elevation of VEGF in
ovarian cancers correlates with worsened patient prognosis, VEGF
in the primary tumour of ovarian cancers is recognized as a
prognostic indicator (Fujimoto et al, 1998b). On the other hand,
although the presence of peritoneal metastasis in ovarian cancers
is critical to patient prognosis (Eisenkop et al, 1993; Kapp et al,
1999), there is as yet no prognostic indicator for peritoneal metas-
tasis-positive patients. This status prompted us to investigate the
clinical significance of VEGF expression in peritoneal metastatic
tumours of ovarian cancers. 
MATERIALS AND METHODS 
Patients 
Informed consent for the following studies were obtained from all
patients and the Research Committee for Human Subjects, Gifu
University School of Medicine. Thirty patients ranging from 32 to
74 years of age underwent operation for ovarian cancer stage III at
the Department of Obstetries and Gynecology, Gifu University
School of Medicine between January 1995 and January 1998
(Table 1). None of the patients had received any preoperative
therapy. A part of the tissues of ovarian cancers (the peritoneal
metastatic lesion and the corresponding primary tumour) was
obtained immediately after the resection and snap-frozen in liquid
nitrogen to determine the levels of VEGF, and a neighbouring part
of the tissues was submitted for histopathological study. The histo-
logical types and clinical stages were determined by International
Federation of Obstetrics and Gynecology (FIGO) classification
(FIGO News, 1989). Twenty-four-month survival rates were
calculated for the 30 patients, all of whom underwent curative
resection for ovarian cancer that achieved macroscopically
disease-free status, and analyzed using the Kaplan–Meier method. 
Immunohistochemistry 
Four-mm sections were cut from formalin-fixed paraffin-
embedded tissue with a microtome and dried overnight at 37˚C on
a silanized-slide (Dako, Carpinteria, CA, USA). Samples were
deparaffinized in xylene at room temperature for 80 min and
washed with a graded ethanol/water mixture and then with
distilled water. The samples for VEGF were soaked in a citrate
buffer and then microwaved at 100˚C for 10 min. The protocol for
DAKO LSAB2 Kit, Peroxidase (Dako) was followed for each
sample. In the described procedure, rabbit anti-human VEGF
antigen VEGF(147) (200 mg/ml, Santa Cruz Biotechnology, Santa
Cruz, CA, USA) as the first antibody was used at a dilution of
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acids 1–147 of VEGF can detect all isoforms of VEGF (wild type
VEGF 206, VEGF 189, VEGF 165, and VEGF 121). The addition of the
first antibody was omitted in the protocol for negative controls. 
Enzyme immunoassay for determination of human
VEGF antigen 
All steps were carried out at 4˚C. Tissues (wet weight: 10–20 mg)
were homogenized in HG buffer (5 mM Tris-HCl, pH 7.4, 5 mM
NaCl, 1 mM CaCl2, 2 mM ethyleneglycol-bis-[b-aminoethyl
ether]-N,N,N¢, N¢-tetraacetic acid, 1 mM MgCl2, 2 mM dithiothre-
itol, 25 mg/ml aprotinin, and 25 mg/ml leupeptin) with a Polytron
homogenizer (Kinematics, Luzern, Switzerland). This suspension
was centrifuged in a microfuge at 12 000 rpm for 3 min to remove
the nuclear pellet. The protein concentration of samples was
measured by the method of Bradford to standardize VEGF antigen
levels (Bradford, 1976). 
VEGF antigen levels in the samples were determined by a sand-
wich enzyme immunoassay using a Human VEGF Assay Kit-IBL
(Immuno Biological Laboratories, Gunma, Japan). The levels of
VEGF were standardized with the corresponding cellular protein
concentrations. 
Statistics 
The levels of VEGF were measured from three parts of the same
tissue of each primary tumour and metastatic lesion in triplicate
(9 determinations each; 18 determinations for each case). The t-
test for two independent samples was used in a one-tail manner to
compare the nine determinations for each primary tumour against
the nine determinations for each metastatic lesion (30 independent
t-tests). Survival curves were calculated using the Kaplan–Meier
method, and analyzed by the log-rank test. Differences were
considered significant when P was less than 0.05. 
RESULTS 
Immunohistochemical staining for VEGF (n = 30) was carried out
to study VEGF localization and the intensity of staining in the
peritoneal metastatic lesion and the corresponding primary
tumour. As shown in Figure 1, positive staining is seen dominantly
in the cytoplasm of the cancer cells, and faintly in interstitial cells.
There was no case of decreased intensity from the primary tumour
to the metastatic lesion. Obviously increased intensity from the
primary tumour to the metastatic lesion was found in 8 of 30 cases
of ovarian cancers. 
Enzyme immunoassay for VEGF was carried out to study
VEGF level in the peritoneal metastatic lesion and the corre-
sponding primary tumour. As shown in Figure 2, there was no
case of decreased VEGF level from the primary tumour to the
metastatic lesion. Significantly, (P < 0.05) increased VEGF level
from the primary tumour to the metastatic lesion was found in 8 of
30 cases, the same cases that showed increased intensity of
immunohistochemical staining for VEGF. 
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Table 1 Patient details 
Case Age (years) Stage Histology Presence of tumour VEGF
1 39 III Serous cyAd, G1 Ov, Pd (Il, Aw), Om, Ly Increased 
2 71 III Serous ppcyAd, G3 Ov, Pd (Il, Sc), Ly Increased 
3 55 III Mucinous cyAd, G1 Ov, Pd (Il, Sc), Om, Ly Increased 
4 71 III Endometrioid Ad, G1 Ov, Pd (Il, Cc, Sc, Lv, Aw), Om, Ly Increased 
5 62 III Serous cyAd, G1 Ov, Pd (Il, Sc, Aw), Ly Increased 
6 35 III Mucinous cyAd, G1 Ov, Pd (Il, Sc, Lv, Aw), Om, Ly Increased 
7 63 III Serous ppcyAd, G2 Ov, Pd (Sc), Il, Om, Ly Increased 
8 69 III Clear cell Ad Ov, Pd (Il, Cc, Sc), Ly Increased 
9 54 III Clear cell Ad Ov, Pd (Cc, Sc), Il, Ly NC 
10 63 III Endometrioid Ad, G1 Ov, Pd (Il, Sc, Aw), Om, Ly NC 
11 50 III Serous ppcyAd, G1 Ov, Pd (Il, Sc, Aw), Om, Ms, Ly NC 
12 67 III Mucinous cyAd, G2 Ov, Pd (Il, Aw), Om, Ly NC 
13 56 III Mucinous cyAd, G1 Ov, Pd (Sc, Aw), Il, Om, Ly NC 
14 34 III Serous cyAd, G3 Ov, Pd (Jj, Sc, Aw), Il, Om, Ms, Ly NC 
15 49 III Endometrioid Ad, G1 Ov, Pd (Il, Sc, Aw), Om, Ly NC 
16 50 III Endometrioid Ad, G1 Ov, Pd (Il, Cc, Aw), Om, Ly NC 
17 54 III Mucinous cyAd, G1 Ov, Pd (Il, Sc, Aw), Ly NC 
18 48 III Endometrioid Ad, G1 Ov, Pd (Sc, Aw), Om, Ly NC 
19 59 III Clear cell Ad Ov, Pd (Sc, Aw), Il, Om, Ly NC 
20 68 III Serous cyAd, G1 Ov, Pd (Cc, Sc), Ly NC 
21 60 III Serous pcyAd, G1 Ov, Pd (Il, Sc, Lv, Aw), Om, Ly NC 
22 74 III Serous cyAd, G1 Ov, Pd (Il, Cc), Ly NC 
23 49 III Serous ppcyAd, G1 Ov, Pd (Il, Sc, Aw), Om, Ms, Ly NC 
24 71 III Clear cell Ad Ov, Pd (Il, Cc, Sc), Om, Ly NC 
25 50 III Mucinous cyAd, G1 Ov, Pd (Il, Aw), Ly NC 
26 64 III Serous cyAd, G1 Ov, Pd (Il, Sc, Aw), Om, Ly NC 
27 67 III Mucinous cyAd, G2 Ov, Pd (Sc, Aw), Il, Om, Ly NC 
28 69 III Endometrioid Ad, G2 Ov, Pd (Il, Cc, Aw), Om NC 
29 44 III Mucinous cyAd, G1 Ov, Pd (Sc) NC 
30 67 III Serous cyAd, G1 Ov, Pd (Il, Sc, Aw), Ly NC 
Ov, ovaries; Pd, peritoneal dissemination; Il, ileum; Cc, caecum; Jj jejunum; Lv, liver; Aw, abdominal wall; Sc, sigmoid colon; Om, omentum;
Ms, mesentery; Ly, pelvic lymph nodes G1, well-differentiated; G2, moderately differentiated, G3, poorly differentiated; Ad, adenocarcinoma;
cyAd, cystadenocarcinoma; ppcyAd, papillary cystadenocarcinoma; Increased, cases with significantly increased VEGF level from the
primary tumour to the peritoneal metastatic lesion; NC, cases with no change in VEGF level from the primary tumour to the peritoneal
metastatic lesion.We analysed the prognosis of the 30 patients who underwent
curative resection and whose 24-month survival rates were calcu-
lated. As shown in Figure 3, the prognosis of patients with signifi-
cantly increased VEGF level was significantly (P < 0.05) poor 
(0.8 = 0%) compared to that of patients with no change in the level
(15/22 = 68%) from the primary tumour to the peritoneal
metastatic lesion.
DISCUSSION 
Newly developed capillary network formation from the original
vessel is designated as neovascularization. Generally, turnover of
capillary endothelial cells is extremely slow to the order of months
or years in physiological neovascularization, while the turnover in
ovary and uterine endometrium is altered to a rapid state within the
ovarian cycle. The turnover with malignant transformation
becomes rapid, which might contribute to the acceleration of
tumour growth (Denekamp, 1984). 
Among angiogenic factors, VEGF has been evaluated as an
important factor for tumour angiogenesis, which is essential for
the growth of solid tumours. Generally speaking, VEGF secreted
from tumours contributes to tumour growth not via an autocrine
pathway to tumour cells, but via a paracrine pathway to
surrounding microvessels (Berkman et al, 1993). The elevation of
VEGF in ovarian cancers correlates with worsened patient prog-
nosis (Fujimoto et al, 1998b). On the other hand, KDR, a receptor
VEGF in metastasis of ovarian cancers 315
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Primary tumour Metastatic lesion
Figure 1 Immunohistochemical staining for VEGF in peritoneal metastatic lesion and corresponding primary tumour of ovarian cancers. This is a
representative case (case 5, serous cystadenocarcinama shown in Figure 2) with increased intensity from the primary tumour to the metastatic lesion 
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Figure 3 Survival rates after curative resection for ovarian cancer. Patient
prognosis was analysed with a 24-month survival rate. Increased: the cases
with significantly increased VEGF level from the primary tumour to the
peritoneal metastatic lesion. No change; the cases with no change in VEGF
level from the primary tumour to the peritoneal metastatic lesion 
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Figure 2 Levels of VEGF in peritoneal metastatic lesion and corresponding
primary tumor of ovarian cancers. The levels of VEGF were determined by a
sandwich enzyme immunoassay using a Human VEGF Assay Kit-IBL
(Immuno Biological Laboratories, Gunma, Japan). Each result is the mean of
9 determinations. Number in l l, living case; number in l, deceased case.
*P < 0.05 vs the corresponding primary tumour of VEGF, is expressed by some ovarian cancer cells that 
co-express VEGF (Boocock et al, 1995). Co-expression of VEGF
and KDR by tumour cells in ovarian cancer raises the possibility
of autocrine stimulation (Boocock et al, 1995). Furthermore, it
facilitates metastasis via neovascularization (Warren et al, 1995).
Although the presence of peritoneal abdominal metastasis is
critical to patient prognosis, there is as yet no prognostic indicator
for peritoneal metastasis-positive patients in ovarian cancers. 
In the present study, it was demonstrated that the prognosis of
patients with increased VEGF level from the primary tumour to
the peritoneal metastatic lesion was extremely poor in comparison
with that of patients with no change in the level. Thus, VEGF may
contribute to the advancement of metastatic lesions, and VEGF
level in metastatic lesions may be a prognostic indicator. This indi-
cates that anti-VEGF and VEGF receptor antibodies (Borgstrom et al,
1996; Yuan et al, 1996; Zhu et al, 1998; Prewett et al, 1999) might be
effective against advanced ovarian cancers, especially the cases with
increased VEGF level from the primary tumour to the metastatic
lesion, apart from a direct anti-tumoural effect on cancer cells.
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